Development of a score for early identification of children with Kawasaki disease requiring second-line treatment in multi-ethnic populations in Europe: A multicentre retrospective cohort study.
Clinical scoring
Coronary artery
Echocardiography
Kawasaki disease
Pediatric rheumatology
Severity score
Vasculitis
Journal
The Lancet regional health. Europe
ISSN: 2666-7762
Titre abrégé: Lancet Reg Health Eur
Pays: England
ID NLM: 101777707
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
entrez:
19
8
2022
pubmed:
20
8
2022
medline:
20
8
2022
Statut:
epublish
Résumé
Early identification of high-risk patients is essential to stratify treatment algorithms of Kawasaki disease (KD) and to appropriately select patients at risk for complicated disease who would benefit from intensified first-line treatment. Several scores have been developed and validated in Asian populations but have shown low sensitivity in predicting intravenous immunoglobulin (IVIG) resistance in non-Asian populations. We sought methods to predict the need for secondary treatment after initial IVIG in non-Asian populations. We conducted a retrospective, multicenter study including consecutive patients with KD admitted to two tertiary pediatric hospitals in France and Italy from 2005 to 2019. We evaluated the performance of the Kawanet-score and compared it with the performances of initial echocardiography findings, and of a newly proposed score combining the Kawanet-score and initial echocardiography findings. For each score, we assessed the AUC, sensitivity and specificity for predicting the need for second-line treatment. We included 363 children with KD, 186 from France and 177 from Italy, of whom 57 (16%) required second-line therapy after the first IVIG dose. The Kawanet score, coronary artery dilation or aneurysm with maximal Z-score ≥2.0 at baseline, and abnormal initial echocardiography had a sensitivity of 43%, 55% and 65% and a specificity of 73%, 78%, 73%, respectively, for predicting the need for second-line treatment. The Kawanet-score was significantly improved by combining it with initial echocardiography findings. The best predictive performance (Sensitivity 76%, Specificity 54%) was obtained by combining the Kawanet-score with abnormal initial echocardiography, defined by the presence of either coronary artery maximal Z-score ≥2.0, pericarditis, myocarditis and/or ventricular dysfunction. This score predicted the need for second-line treatment in European, African/Afro-Caribbean and Asian ethnicity with a sensitivity of 80%, 65% and 100%, respectively, and a specificity of 56%, 51% and 61%, respectively. Our study proposes a score that we named the Kawanet-echo score, which allows early identification of children with KD who require a second-line treatment in multi-ethnic populations in Europe. None.
Sections du résumé
Background
UNASSIGNED
Early identification of high-risk patients is essential to stratify treatment algorithms of Kawasaki disease (KD) and to appropriately select patients at risk for complicated disease who would benefit from intensified first-line treatment. Several scores have been developed and validated in Asian populations but have shown low sensitivity in predicting intravenous immunoglobulin (IVIG) resistance in non-Asian populations. We sought methods to predict the need for secondary treatment after initial IVIG in non-Asian populations.
Methods
UNASSIGNED
We conducted a retrospective, multicenter study including consecutive patients with KD admitted to two tertiary pediatric hospitals in France and Italy from 2005 to 2019. We evaluated the performance of the Kawanet-score and compared it with the performances of initial echocardiography findings, and of a newly proposed score combining the Kawanet-score and initial echocardiography findings. For each score, we assessed the AUC, sensitivity and specificity for predicting the need for second-line treatment.
Findings
UNASSIGNED
We included 363 children with KD, 186 from France and 177 from Italy, of whom 57 (16%) required second-line therapy after the first IVIG dose. The Kawanet score, coronary artery dilation or aneurysm with maximal Z-score ≥2.0 at baseline, and abnormal initial echocardiography had a sensitivity of 43%, 55% and 65% and a specificity of 73%, 78%, 73%, respectively, for predicting the need for second-line treatment. The Kawanet-score was significantly improved by combining it with initial echocardiography findings. The best predictive performance (Sensitivity 76%, Specificity 54%) was obtained by combining the Kawanet-score with abnormal initial echocardiography, defined by the presence of either coronary artery maximal Z-score ≥2.0, pericarditis, myocarditis and/or ventricular dysfunction. This score predicted the need for second-line treatment in European, African/Afro-Caribbean and Asian ethnicity with a sensitivity of 80%, 65% and 100%, respectively, and a specificity of 56%, 51% and 61%, respectively.
Interpretation
UNASSIGNED
Our study proposes a score that we named the Kawanet-echo score, which allows early identification of children with KD who require a second-line treatment in multi-ethnic populations in Europe.
Funding
UNASSIGNED
None.
Identifiants
pubmed: 35982834
doi: 10.1016/j.lanepe.2022.100481
pii: S2666-7762(22)00177-6
pmc: PMC9379661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100481Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
All authors: None to declare.
Références
Int J Rheum Dis. 2018 Jan;21(1):50-55
pubmed: 29152929
Eur J Pediatr. 2007 Feb;166(2):131-7
pubmed: 16896641
Am J Ther. 2016 Nov/Dec;23(6):e1293-e1299
pubmed: 25611359
Sci Rep. 2020 Feb 20;10(1):3125
pubmed: 32080307
Cochrane Database Syst Rev. 2017 Jan 27;1:CD011188
pubmed: 28129459
Circ Cardiovasc Qual Outcomes. 2021 Feb;14(2):e007191
pubmed: 33541111
Arch Dis Child. 2011 Nov;96(11):1088-90
pubmed: 20551193
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
J Am Heart Assoc. 2019 Jun 4;8(11):e011319
pubmed: 31130036
Int J Mol Sci. 2016 Feb 24;17(3):278
pubmed: 26927060
J Am Heart Assoc. 2017 May 31;6(6):
pubmed: 28566299
Circulation. 2006 Jun 6;113(22):2606-12
pubmed: 16735679
Arch Dis Child. 2013 Feb;98(2):97-102
pubmed: 23235890
Arch Dis Child. 2015 Apr;100(4):366-8
pubmed: 25670405
J Am Soc Echocardiogr. 2011 Jan;24(1):60-74
pubmed: 21074965
Front Pediatr. 2021 Sep 30;9:748467
pubmed: 34660496
Rheumatology (Oxford). 2019 Apr 1;58(4):656-671
pubmed: 30535249
J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):25-29
pubmed: 28062554
Pediatr Rheumatol Online J. 2018 Jul 18;16(1):48
pubmed: 30021610
J Pediatr. 2006 Aug;149(2):237-40
pubmed: 16887442
Lancet. 2012 Apr 28;379(9826):1613-20
pubmed: 22405251
Lancet. 2019 Mar 16;393(10176):1128-1137
pubmed: 30853151
Pediatr Res. 2022 Feb;91(3):621-626
pubmed: 33753891
Pediatrics. 2000 Jun;105(6):E78
pubmed: 10835091